Rapid Dose Therapeutics Corp. announced the resignation of Donald Sheldon as a director of the Corporation and Miles Nagamatsu as its Chief Financial Officer, both resignations being effective February 20, 2020, due to the pending expiry of the Corporation's current D&O insurance coverage. Both Mr. Sheldon and Mr. Nagamatsu have indicated a willingness to be re-appointed as soon as replacement insurance policies can be secured by the Corporation with an alternate insurer.

In the interim, Mr. Sheldon will be continuing to serve the Corporation as legal counsel and Mr. Nagamatsu will be continuing to serve as a consultant. Rishi Kapadia, Controller, will temporarily assume and perform the responsibilities of Chief Financial Officer. Jason Lewis, SVP of Business Development, has been appointed as a director of the Corporation, effective February 21, 2020.